Trials Sponsors Conditions Drugs Pricing

Conditions

Epithelium, Corneal

Keywords

Removal of corneal epithelium followed by excimer laser treatment during prk

Outcome Measures

Primary Outcomes (1)

Corneal Epithelial Healing Time
patients' eyes will be observed daily after surgery until the corneal epithelium has completely healed (usually 3 to 4 days)
3 to 4 days after surgery

Study Arms (2)

Moxifloxacin

EXPERIMENTAL

Moxifloxacin eye drops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery

Drug: Moxifloxacin

Gatifloxacin

EXPERIMENTAL

Gatifloxacin eyedrops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery

Drug: Gatifloxacin

Interventions

MoxifloxacinDrug

1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery

Moxifloxacin

GatifloxacinDrug

1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery

Gatifloxacin

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age21 Years+

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Manifest refraction spherical equivalent (MSE) of up to -6.00 diopters (D) at the spectacle plane with refractive cylinder up to 3.00D.

You may not qualify if:

Sponsors & Collaborators

Walter Reed Army Medical Center
US federal agencylead

Study Sites (1)

Walter Reed Army Medical Center

Washington D.C., District of Columbia, 20307, United States

MeSH Terms

Interventions

MoxifloxacinGatifloxacin

Intervention Hierarchy (Ancestors)

Fluoroquinolones4-QuinolonesQuinolonesQuinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Results Point of Contact

Title: Principal Investigator
Organization: U.S. Army Warfighter Refractive Surgery Research Center

Study Officials

KRAIG S. BOWER, MD
Walter Reed Army Medical Center
PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee: No
Restriction Type: OTHER
Restrictive Agreement: Yes

Enrollment

40 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: DOUBLE
Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: FED

Study Record Dates

First Submitted

December 19, 2006

First Posted

December 20, 2006

Primary Completion

February 2005

Actual (reported)

Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Primary Completion

Study Completion

First Submitted

First Posted

Results Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Moxifloxacin

Gatifloxacin

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Primary Completion

Study Completion

First Submitted

First Posted

Results Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Moxifloxacin

Gatifloxacin

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

Source record

Locations